RESUMO
Belgian general practitioners studied the effect of enalapril over a period of 6 months on hypertension and quality of life in 4988 patients, whose hypertensive condition remained uncontrolled by previous treatments and/or in whom this previous drug regimen was not tolerated. Blood pressure was reduced from an average of 170/101 mm Hg at the onset of the trial to 145/85.5 mm Hg after 24 weeks. The treatment with enalapril was well tolerated and tolerance improved remarkably in the patients, whose previous treatment had caused intolerance. Quality of life, determined by means of the Nottingham Health Profile questionnaire, was favourably influenced in the patients participating in this study.
Assuntos
Enalapril/uso terapêutico , Hipertensão/tratamento farmacológico , Qualidade de Vida , Adulto , Idoso , Bélgica , Pressão Sanguínea/efeitos dos fármacos , Indicadores Básicos de Saúde , Humanos , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Fatores de TempoRESUMO
1 The uricosuric effect of diflunisal was studied in eleven normal subjects. 2 Urine and serum uric acid levels were measured and used to assess the effect. 3 Diflunisal caused statistically significant decreases in serum uric acid levels and increases in uric acid clearance at 250 and 375 mg twice daily. 4 Diflunisal taken on an empty stomach caused epigastric discomfort in the high dose group which was obviated when the drug was taken with meals. 5 Diflunisal caused no abnormalities in the measured haematological, urological or biochemical parameters.
Assuntos
Analgésicos/farmacologia , Salicilatos/farmacologia , Uricosúricos , Adulto , Analgésicos/efeitos adversos , Método Duplo-Cego , Humanos , Masculino , Placebos , Salicilatos/efeitos adversos , Fatores de Tempo , Ácido Úrico/sangueRESUMO
Fecal blood loss was evaluated in normal subjects with 51Cr-labeled red cells. In a double-blind parallel study in 10 subjects, 250 mg diflunisal twice daily did not significantly increase blood loss in two consecutive treatment periods, while 750 mg acetylsalicylic acid (ASA) 4 times daily did so. In a double-blind crossover study in 2 subjects, diflunisal, 250 mg twice daily again did not significantly affect fecal blood loss during a 4-day treatment period, and there also was no significant effth diflunisal during two additional treatment days. ASA, 600 mg 4 times daily, induced an increase in blood loss and this effect was significantly enhanced by the addition of alcohol. The difference between treatments in the way they interact with alcohol was also statistically significant.
Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Aspirina/efeitos adversos , Etanol/efeitos adversos , Hemorragia Gastrointestinal/induzido quimicamente , Salicilatos/efeitos adversos , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Interações Medicamentosas , Humanos , MasculinoRESUMO
Faecal blood loss was measured in normal male volunteers using 51Cr-labelled red cells. In a double-blind parallel study in 10 subjects, the effect of 250 mg diflunisal twice daily was compared with 750 mg aspirin 4-times daily. Drugs were taken during two 7-day periods separated by a 1-week control period. Mean daily faecal blood loss during the two treatment periods was 0.32 ml and 0.53 ml in the diflunisal group versus 6.87 ml and 3.20 ml in the aspirin group. Diflunisal did not significantly increase blood loss, while aspirin had a significant effect. In a double-blind crossover study in 12 subjects, the effect of 250 mg diflunisal twice daily was compared with 600 mg aspirin 4-times daily. Alcohol (120 ml, 40%) was added during the last 2 days of each 6-day treatment period. Faecal blood loss was not significantly affected by diflunisal and there was also no significant effect on blood loss when alcohol was co-administered. Aspirin significantly increased faecal blood loss and this effect was significantly enhanced by the addition of alcohol.
